TKNO vs AZTA vs BRKR vs NTRA vs PACB

For growth investors, Natera, Inc.

(NTRA) is the stronger pick with 35. 9% revenue growth year-over-year, versus 2. 1% for Bruker Corporation (BRKR). Analysts rate Alpha Teknova, Inc. (TKNO) a "Buy" — based on 3 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Natera, Inc.

(NTRA) delivered a total return of +115. 9%, compared to -93. 4% for Pacific Biosciences of California, Inc. (PACB). Over 10 years, the gap is even starker: NTRA returned +20. 9% versus TKNO's -84. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Natera, Inc.

(NTRA) is the lower-risk stock at 1. 26β versus Pacific Biosciences of California, Inc. 's 2. 43β — meaning PACB is approximately 93% more volatile than NTRA relative to the S&P 500. On balance sheet safety, Azenta, Inc. (AZTA) carries a lower debt/equity ratio of 6% versus 142% for Pacific Biosciences of California, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Natera, Inc.

(NTRA) is pulling ahead at 35. 9% versus 2. 1% for Bruker Corporation (BRKR). On earnings-per-share growth, the picture is similar: Azenta, Inc. grew EPS 60. 5% year-over-year, compared to -119. 7% for Bruker Corporation. Over a 3-year CAGR, NTRA leads at 41. 1% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Bruker Corporation (BRKR) is the more profitable company, earning -0.

3% net margin versus -341. 5% for Pacific Biosciences of California, Inc. — meaning it keeps -0. 3% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BRKR leads at 6. 9% versus -348. 5% for PACB. At the gross margin level — before operating expenses — NTRA leads at 64. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Bruker Corporation (BRKR) trades at 20.

7x forward P/E versus 23. 7x for Azenta, Inc. — 3. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for AZTA: 140. 5% to $44. 67.

In this comparison, BRKR (0.

3% yield) pays a dividend. TKNO, AZTA, NTRA, PACB do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Natera, Inc.

(NTRA) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1. 26)). Pacific Biosciences of California, Inc. (PACB) carries a higher beta of 2. 43 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (NTRA: +20. 9%, PACB: -81. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: TKNO is a small-cap quality compounder stock; AZTA is a small-cap quality compounder stock; BRKR is a small-cap quality compounder stock; NTRA is a mid-cap high-growth stock; PACB is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.